Iterion Therapeutics

About:

Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.

Website: https://iteriontherapeutics.com/

Top Investors: Lumira Ventures, AngelMD, Cancer Prevention and Research Institute of Texas, Sante Ventures, GOOSE Capital

Description:

Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada. It was founded in 2010 and is headquartered in Houston, Texas.